Rising prevalence of chronic diseases such as cancer and cardiovascular diseases, increasing number of surgical procedures performed across the globe, and growing investments in RD activities to expand clinical applications of heparin are some key factors expected to drive market growth
The global heparin market size is expected to reach USD 7.55 Billion in 2028 at a CAGR of 1.4% during the forecast period, according to the latest report by Reports and Data. Rising demand for heparin due to high prevalence of chronic conditions such as last-stage renal disease, atrial fibrillation, and cardiovascular diseases, increasing number of surgical procedures performed across the globe, and extensive RD activities to explore other clinical and therapeutic roles of heparin are key factors expected to drive market revenue growth over the forecast period. In addition, heparin is used for various off-label indications in hospitals and for treatment and prevention of venous thromboembolism events in post-surgical patients, and this is another factor expected to contribute to revenue growth of the market going ahead.
Heparin is a widely used anticoagulant that significantly reduces clotting risks and thromboembolism events after major surgical interventions. Heparin is a naturally occurring polysaccharide belonging to the family of glycosaminoglycans that are primarily present in mast cell. Heparin exerts anticoagulant properties by binding to antithrombin and enhancing the subsequent inhibitory effect of antithrombin on thrombin and activated factor X. The currently available heparin is mostly obtained from animal tissue. However, due to growing concerns regarding animal safety, several approaches for bioengineering heparin such as microbial production and chemoenzymatic modification among others are increasingly being researched on. Major players are also focusing on RD for its potential clinical and therapeutic applications such as anti-inflammatory and anti-tumor activities as well as role in prevention of infectious diseases, besides its use as an anticoagulant. Heparin has antineoplastic properties along with anticoagulant properties, and this is expected to result in increasing research activities to explore potential of heparin for treating various other conditions. This, in turn, is expected to significantly contribute to market revenue growth going ahead.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC])@ https://www.reportsanddata.com/sample-enquiry-form/4154
The report puts an emphasis on the information regarding the key players with a special focus on their company profile, business overview, recent advancements, product catalog, and strategic business plans. It provides a comprehensive overview of the strategic alliances in the market under taken by the key players such as mergers and acquisitions, joint ventures, collaborations, partnerships, agreements, product launches, brand promotions, and corporate deals, among others.
Key companies operating in the market and profiled in the report include:
Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sanofi SA, B. Braun Melsungen AG, GlaxoSmithKline PLC, LEO Pharma A/S, Aspen Holdings, Fresenius SE Co. KGaA, and Viatris Inc.
Order This Report@ https://www.reportsanddata.com/report-pricing/4154
The Heparin market takes into account major geographical locations such as North America, Europe, Asia Pacific, Latin America, and Middle East Africa to offer key insights into market growth, market size, market share, revenue growth, current and emerging trends, supply and demand ratio, import/export, consumer demand and behavior, and presence of key players in each region. The report offers an in-depth country wise analysis to impart better understanding of the market and its growth prospects.
Segments Covered in the report
Product Type Outlook (Revenue, USD Billion; 2018-2028)
- Unfractionated Heparin
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
Route of Administration (Revenue, USD Billion; 2018-2028)
- Subcutaneous
- Intravenous
Application Outlook (Revenue, USD Billion; 2018-2028)
- Coronary Artery Disease
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Others
Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Key Regions Analyzed in the Report include:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of MEA
Furthermore, it consists information about individual segment of the Heparin market based on the types and application. The report also offers insights about the key segments expected to register significant revenue growth over the forecast period and primary trends influencing their growth. It also offers CAGR and market share values for each segment to provide clear understanding of demand and trend in the global market.
Some Key Highlights from the Report:
- Low-molecular-weight heparin (LMWH) segment is expected to account for largest revenue share over the forecast period, attributable to increasing preference for LMWH over unfractionated heparin in clinical settings, in treatment of venous thromboembolism events, and in obstetrics due to low risk of bleeding and other complications associated with it.
- Subcutaneous route of administration is expected to register significant revenue growth during the forecast period, owing to growing preference for subcutaneous therapy of heparin, lesser incidence of pain and higher patient comfort, and low risk of recurrent thromboembolism when treated with subcutaneous injection of low-molecular weight heparin.
- Venous thromboembolism is expected to dominate other application segments between 2021 and 2028 owing to increasing incidence of VTE among post-operative patients and rising need for anticoagulant therapy with low-molecular weight heparin.
- Hospital pharmacies segment is expected to register steady revenue CAGR over the forecast period, attributable to increasing hospital admission of patients needing surgeries or dialysis, availability of high-quality heparin derivatives, growing number of outpatient procedures, and increasing reliance on pharmacists and doctors.
- North America is expected to account for a significantly large revenue share over the forecast period, attributable to rising incidence of cardiovascular diseases and chronic illnesses, rising number of surgical procedures performed, availability of high-end medical facilities and medications, and robust presence of key players in the market.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4154
Thank you for reading our report. For any specific details on customization of this report, please get in touch with us. We will ensure the report you get is well-suited to your needs.
Explore More Industry Research by Reports and Data:
Intravenous Immunoglobin (IVIG) Market @ https://www.biospace.com/article/increase-in-prevalence-of-immunodeficiency-diseases-and-rise-in-adoption-of-immunoglobulin-therapies-are-key-factors-driving-ivig-market-revenue-growth/
Advanced Wound Care Market @ https://www.biospace.com/article/advanced-wound-care-market-synopsis-2022-2030-growing-prevalence-of-diseases-affecting-wound-healing-capabilities/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
